Share This

萬邦德:子公司產品獲得美國FDA罕見兒科疾病藥物認定

2024-05-07T16:07

... 5月7日,萬邦德公告,全資子公司萬邦德制藥集團有限公司於2024年5月1日收到美國食品藥品監督管理局(FDA)的認定函,石杉堿甲用於治療新生兒缺氧缺血性腦病(HIE)獲得FDA授予的「罕見兒科疾病」(Rare Pediatric Disease,RPD)藥物認定。(財聯社)

...
 recommend this page to friend   Details 
 
 
 Related news
  Search   More 
 Latest News
  Search   More 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.